Victoza Injection
Product Images NDC 50090-2853

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Victoza (NDC 50090-2853). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Structural Formula Of Liraglutide (49f302f5 F315 48b8 83a4 6ca56f01fded 01)

Figure 1: Structural Formula Of Liraglutide (49f302f5 F315 48b8 83a4 6ca56f01fded 01)
FDA Label Image

Figure 2 Mean Insulin Secretion Rate (isr) Versus Glucose Concentration (49f302f5 F315 48b8 83a4 6ca56f01fded 02)

Figure 2 Mean Insulin Secretion Rate (isr) Versus Glucose Concentration (49f302f5 F315 48b8 83a4 6ca56f01fded 02)
This is a graph showing the effect of 15K pmol/kg/min dose of Victoza compared to Placebo on plasma glucose levels (mg/dL). Any additional information or context is not available from the given text.*
FDA Label Image

Figure 4 Mean Hba1c For Patients Who Completed The 26-week Trial And For The Last Observation Carried Forward (locf, Intent-to-treat) Data At Week 26 (49f302f5 F315 48b8 83a4 6ca56f01fded 04)

Figure 4 Mean Hba1c For Patients Who Completed The 26-week Trial And For The Last Observation Carried Forward (locf, Intent-to-treat) Data At Week 26 (49f302f5 F315 48b8 83a4 6ca56f01fded 04)
FDA Label Image

Victoza Pen And Needle (Image 01)

Victoza Pen And Needle (Image 01)
The text is describing the components of a Victoza® Pen used for insulin injections. It includes details about the rubber cartridge tip, the dose control, the display pointer, and the needle. In case of any issues, the user is instructed to call the toll-free number or visit the website provided.*
FDA Label Image

Fig. A (Pull off pen cap)

Fig. A (Pull off pen cap)
FDA Label Image

Fig. B (Remove protective tab.)

Fig. B (Remove protective tab.)
FDA Label Image

Fig. C And D (- Image 04)

Fig. C And D (- Image 04)
FDA Label Image

Fig. E (Image 05)

Fig. E (Image 05)
FDA Label Image

Fig. F (Image 06)

Fig. F (Image 06)
FDA Label Image

Fig. G (Image 07)

Fig. G (Image 07)
FDA Label Image

Fig. H (Pull off pen cap.)

Fig. H (Pull off pen cap.)
FDA Label Image

Fig. I (Image 09)

Fig. I (Image 09)
FDA Label Image

Fig. J-k (Image 10)

Fig. J-k (Image 10)
FDA Label Image

Fig. L (Image 11)

Fig. L (Image 11)
FDA Label Image

Fig. M (Image 12)

Fig. M (Image 12)
FDA Label Image

Fig. N (Image 13)

Fig. N (Image 13)
FDA Label Image

Fig. O (Image 14)

Fig. O (Image 14)
FDA Label Image

Fig. P (Image 15)

Fig. P (Image 15)
FDA Label Image

Fig. Q (Image 16)

Fig. Q (Image 16)
FDA Label Image

Figure 5 (Image 20)

Figure 5 (Image 20)
This appears to be a graph or chart depicting the effectiveness of a drug called Victoza compared to a placebo. The x-axis measures time from randomization in months, and the y-axis measures the number of patients at risk. The chart displays data up to 54 months, with patients at risk decreasing over time. The HR (hazard ratio) for Victoza is given as 0.87 with a 95% confidence interval. The text indicates this is the full analysis set.*
FDA Label Image

Figure 3 (Image 21)

Figure 3 (Image 21)
FDA Label Image

Label Image (Lbl500902853)

Label Image (Lbl500902853)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.